Semaglutide

GLP1-S

Price range: $65.00 through $100.00

GLP1-S is a revolutionary GLP-1 receptor agonist that has transformed metabolic research. This long-acting synthetic peptide mimics the body’s natural incretin hormones, offering researchers a powerful tool for studying glucose regulation, weight management, and cardiovascular health.

With its once-weekly dosing potential and impressive efficacy profile, GLP1-S provides unique insights into metabolic control mechanisms. Each vial contains pure, lyophilized powder for reconstitution. This product is exclusively for laboratory research and not for human or animal use.

Overview

GLP1-S represents a major advancement in GLP-1 receptor agonist research. By closely mimicking the body’s natural GLP-1 hormone but with dramatically extended activity, this peptide allows researchers to study metabolic processes with unprecedented precision.

What makes GLP1-S particularly valuable is its ability to influence multiple metabolic pathways simultaneously – from insulin secretion and appetite control to cardiovascular function – making it a versatile tool for comprehensive metabolic research.

This product is strictly for research purposes only. Not approved for human or animal use.

Key Characteristics

MOLECULAR PROFILE

Formula: C₁₈₇H₂₉₁N₄₅O₅₉

Weight: 4113.641 g/mol

CAS: 910463-68-2

Structure: Modified GLP-1 analog

PHYSICAL PROPERTIES

Form: White lyophilized powder

Solubility: Water-soluble

Half-life: Extended duration

Storage: Keep refrigerated 36‑46 °F (2‑8 °C)

How It Works

GLP1-S operates through sophisticated metabolic mechanisms:

Primary Mechanisms

GLP-1 Receptor Activation

Binds to and activates GLP-1 receptors throughout the body

Glucose-Dependent Insulin Release

Stimulates insulin only when blood sugar is elevated

Glucagon Suppression

Reduces glucagon secretion from alpha cells

Gastric Emptying Delay

Slows food movement through the digestive system

Central Appetite Control

Acts on brain centers to reduce hunger and increase satiety

Metabolic Effects

Beta Cell Protection

Helps preserve pancreatic function

Improved Insulin Sensitivity

Enhances tissue response to insulin

Lipid Metabolism

Improves fat oxidation and reduces lipogenesis

Energy Homeostasis

Rebalances energy intake and expenditure

Research Findings

Extensive research has revealed GLP1-S’s remarkable potential across multiple therapeutic areas:

Glycemic Control

Studies demonstrate exceptional blood sugar management:

Significant HbA1c reductions (1.5-2.0%)
Improved fasting glucose levels
Better postprandial glucose control
Reduced glucose variability
Low risk of hypoglycemia when used alone

Weight Management

Research shows impressive weight loss effects:

Average weight loss of 15-20% in obesity
Preferential loss of visceral fat
Preservation of lean muscle mass
Sustained weight loss maintenance
Improvements in body composition

Cardiovascular Benefits

Studies reveal significant cardiovascular protection:

Reduced major cardiovascular events
Lower blood pressure
Improved lipid profiles
Decreased inflammation markers
Better endothelial function
Reduced atherosclerosis progression

Appetite & Satiety

Research demonstrates effects on eating behavior:

Decreased hunger sensations
Increased feelings of fullness
Reduced food cravings
Lower preference for high-fat foods
Improved eating control

Metabolic Syndrome Components

Studies show comprehensive metabolic improvements:

Reduced waist circumference
Improved insulin resistance
Better blood pressure control
Enhanced HDL cholesterol
Decreased triglycerides

Liver Health

Research indicates hepatic benefits:

Reduced liver fat content
Improved NAFLD/NASH markers
Better liver enzyme profiles
Decreased hepatic inflammation
Potential fibrosis improvement

Kidney Function

Studies suggest renal protection:

Reduced albuminuria
Slower kidney function decline
Lower kidney disease progression
Improved renal outcomes in diabetes

Potential Side Effects in Research

Researchers should monitor for these common effects:

Gastrointestinal

Nausea (most common), vomiting, diarrhea, constipation

Appetite

Decreased appetite (often desired effect)

Injection Site

Mild local reactions

General

Occasional headaches, initial fatigue

Rare

Gallstone formation

Note: Gastrointestinal effects typically diminish with continued use and dose titration.

IMPORTANT: This product is exclusively for laboratory research purposes and is not approved for human or veterinary use.

References

  1. Wilding JPH, et al. “Once-Weekly GLP1-S in Adults with Overweight or Obesity.” N Engl J Med. 2021.
  2. Kosiborod MN, et al. “Semaglutide in heart failure with preserved ejection fraction and obesity.” N Engl J Med. 2023.
  3. Ryan DH, et al. “Semaglutide for weight management and heart failure: The SELECT trial 4-year outcomes.” N Engl J Med. 2024.
  4. Liang W, et al. “Semaglutide and neuroprotection in Alzheimer disease: The EVOKE trials.” JAMA. 2024.
  5. Davies M, et al. “GLP1-S 2.4 mg once a week in adults with overweight or obesity.” Lancet. 2021.
  6. Perkovic V, et al. “Effects of semaglutide on chronic kidney disease in type 2 diabetes.” N Engl J Med. 2024.
  7. Müller TD, et al. “GLP-1 receptor agonists for metabolic disorders: From mechanisms to medicines.” Nature. 2023.
  8. Lincoff AM, et al. “GLP1-S and cardiovascular outcomes in obesity without diabetes.” N Engl J Med. 2023.
  9. Newsome PN, et al. “A Placebo-Controlled Trial of Subcutaneous GLP1-S in NASH.” N Engl J Med. 2021.
  10. Rubino DM, et al. “Effect of weekly subcutaneous semaglutide on weight loss maintenance.” JAMA. 2021.

Third-Party Lab Tested

View our independent laboratory test certificate showing purity and composition analysis.


📋 View Test Certificate →

Weight N/A
Dimensions N/A
Size

10mg, 15mg, 5mg
SKU: OATH-SEMAGLUTIDE Category: Tags: , ,
Lab Tested and Shipped from the USA
Free Bacteriostatic Water
Free Shipping on Orders Over $200
The Purest Peptides. Period.
Updating…
Cart Close
  • No products in the cart.

Continue shopping